Sleep and circadian rhythm dysregulation in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 43, Issue , 2013, Pages 209-216

  Monti, Jaime M ^a   BaHammam, Ahmed S ^b   Pandi Perumal, Seithikurippu R ^c   Bromundt, Vivien ^d   Spence, D Warren ^e   Cardinali, Daniel P ^f   Brown, Gregory M ^g  

^a HOSPITAL DE CLÍNICAS   (Uruguay)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c SOMNOGEN CANADA INC   (Canada)

^d UNIVERSITY OF BASEL   (Switzerland)

^e not available   (Canada)

^f PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Circadian rhythms; Schizophrenia; Sleep

Indexed keywords

AGOMELATINE; APOMORPHINE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BIOLOGICAL MARKER; BROMOCRIPTINE; CLOZAPINE; CORTICOSTERONE; CRYPTOCHROME 1; DOPAMINE; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; LONG ACTING DRUG; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; OREXIN; PER1 PROTEIN; PER2 PROTEIN; PERGOLIDE; PLACEBO; RAMELTEON; RISPERIDONE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNINDEXED DRUG; ZIPRASIDONE;

ACTIMETRY; ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; AROUSAL; ASMT GENE; BINDING AFFINITY; BMAL1 GENE; CHRONIC DISEASE; CIRCADIAN RHYTHM DYSFUNCTION; CIRCADIAN RHYTHM SLEEP DISORDER; CLOCK GENE; COGNITIVE DEFECT; CONTROLLED RELEASE FORMULATION; CRY1 GENE; DISEASE EXACERBATION; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG APPROVAL; DRUG CHOICE; DRUG DEPENDENCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERANCE; EVENING DOSAGE; FATALITY; GABAERGIC TRANSMISSION; GENE; GENE ACTIVITY; GENE EXPRESSION; HUMAN; INSOMNIA; METABOLIC DISORDER; NARCOLEPSY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NONREM SLEEP; PARASOMNIA; PATHOPHYSIOLOGY; PER1 GENE; PHYSICAL DISEASE BY BODY FUNCTION; POLYSOMNOGRAPHY; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; REVIEW; SALIVA LEVEL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP; SLEEP QUALITY; SLEEP TIME; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS; SYNAPTIC TRANSMISSION; WAKEFULNESS;

EID: 84873189875     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.12.021     Document Type: Review

References (134)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004, 7(Suppl. 1):S1-S5.
2. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998, 155:761-767.
3. Afonso P., Figueira M.L., Paiva T. Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls. Int J Psychiatry Clin Pract 2011, 15:311-315.
4. Alexiuk N.A., Vriend J. Effects of daily afternoon melatonin administration on monoamine accumulation in median eminence and striatum of ovariectomized hamsters receiving pargyline. Neuroendocrinology 1991, 54:55-61.
5. Alexiuk N.A.M., Vriend J.P. Melatonin reduces dopamine content in the neurointermediate lobe of male syrian-hamsters. Brain Res Bull 1993, 32:433-436.
6. Alexiuk N.A.M., Vriend J. Melatonin: Effects on dopaminergic and serotonergic neurons of the caudate nucleus of the striatum of male syrian hamsters. J Neural Transm 2007, 114:549-554.
7. Alexiuk N.A.M., Uddin M., Vriend J. Melatonin increases the in situ activity of tyrosine hydroxylase in the mediobasal hypothalamus of male syrian hamsters. Life Sci 1996, 59:687-694.
8. Anonymous Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Press, Washington, D.C., [DSM-IV-TR]. Fourth ed.
9. Arinami T., Ohtsuki T., Ishiguro H., Ujike H., Tanaka Y., Morita Y., et al. Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet 2005, 77:937-944.
10. Aston C., Jiang L., Sokolov B.P. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 2004, 77:858-866.
11. Baandrup L., Gasse C., Jensen V.D., Glenthoj B.Y., Nordentoft M., Lublin H., et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010, 71:103-108.
12. Baandrup L., Fagerlund B., Jennum P., Lublin H., Hansen J.L., Winkel P., et al. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: A randomized clinical trial - the SMART trial protocol. BMC Psychiatry 2011, 11:160.
13. Baldessarini R.J. Drugs for the treatment of psychiatric disorders. The pharmacological basis of therapeutics 1996, 399-459. McGraw-Hill, New York, [chapter 18]. 9th ed. J.G. Hardman, L.E. Limbird (Eds.).
14. Benca R.M., Obermeyer W.H., Thisted R.A., Gillin C.J. Sleep and psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 1992, 49:651-668.
15. Benloucif S., Burgess H.J., Klerman E.B., Lewy A.J., Middleton B., Murphy P.J., et al. Measuring melatonin in humans. J Clin Sleep Med 2008, 4:66-69.
16. Bersani G., Mameli M., Garavini A., Pancheri P., Nordio M. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuroendocrinol Lett 2003, 24:181-184.
17. Borba C.P., Fan X., Copeland P.M., Paiva A., Freudenreich O., Henderson D.C. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol 2011, 31:653-658.
18. Borbély A.A. A two process model of sleep regulation. Hum Neurobiol 1982, 1:195-204.
19. Brambilla F., Scarone S., Pugnetti L., Massironi R., Penati G., Nobile P. Bromocriptine therapy in chronic schizophrenics: effects on symptomatology, sleep patterns, and prolactin response to stimulation. Psychiatry Res 1983, 8:159-169.
20. Brannen J.O., Jewett R.E. Effects of selected phenothiazines on REM sleep in schizophrenics. Arch Gen Psychiatry 1969, 221:284-290.
21. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997, 94:2569-2574.
22. Bromundt V., Köster M., Georgiev-Kill A., Opwis K., Wirz-Justice A., Stoppe G., et al. Sleep-wake cycles and cognitive functioning in schizophrenia. Br J Psychiatry 2011, 198:269-276.
23. Brown G.M., Pandi-Perumal S.R., Trakht I., Cardinali D.P. Melatonin and its relevance to jet lag. Travel Med Infect Dis 2009, 7:69-81.
24. Brunner P., Sozer-Topcular N., Jockers R., Ravid R., Angeloni D., Fraschini F., et al. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur J Histochem 2006, 50:311-316.
25. Cardinali D.P., Cano P., Jimenez-Ortega V., Esquifino A.I. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology 2011, 93:133-142.
26. Cardinali D.P., Srinivasan V., Brzezinski A., Brown G.M. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012, 52:365-375.
27. Carlsson A., Lindquist M. Effects of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963, 20:140-144.
28. Carlsson A., Waters N., Holm-Waters S., Tedraff S., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Ann Rev Pharmacol Toxicol 2001, 41:237-260.
29. Carroll L.S., Kendall K., O'Donovan M.C., Owen M.J., Williams N.M. Evidence that putative ADHD low risk alleles at SNAP25 may increase the risk of schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:893-899.
30. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 2008, 22:939-962.
31. Deery M.J., Maywood E.S., Chesham J.E., Sladek M., Karp N.A., Green E.W., et al. Proteomic analysis reveals the role of synaptic vesicle cycling in sustaining the suprachiasmatic circadian clock. Curr Biol 2009, 19:2031-2036.
32. Dibner C., Schibler U., Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010, 72:517-549.
33. Ding J.M., Chen D., Weber E.T., Faiman L.E., Rea M.A., Gillette M.U. Resetting the biological clock: mediation of nocturnal circadian shifts by glutamate and NO. Science 1994, 266:1713-1717.
34. Dubocovich M.L. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983, 306:782-784.
35. Eisenberg D.P., Kohn P.D., Baller E.B., Bronstein J.A., Masdeu J.C., Berman K.F. Seasonal effects on human striatal presynaptic dopamine synthesis. J Neurosci 2010, 30:14691-14694.
36. Fanous A.H., Zhao Z., van den Oord E.J., Maher B.S., Thiselton D.L., Bergen S.E., et al. Association study of SNAP25 and schizophrenia in irish family and case-control samples. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:663-674.
37. Fatemi S.H., Earle J.A., Stary J.M., Lee S., Sedgewick J. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. Neuroreport 2001, 12:3257-3262.
38. Feinberg I., Koresko R.L., Gottlieb F., Wender P.H. Sleep electroencephalographic and eye-movement patterns in schizophrenic patients. Compr Psychiatry 1964, 5:44-53.
39. Ferrier I.N., Arendt J., Johnstone E.C., Crow T.J. Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. Clin Endocrinol 1982, 17:181-187.
40. Ganguli R., Reynolds C.F., Kupfer D.J. Electroencephalographic sleep in young, never-medicated schizophrenics. Arch Gen Psychiatry 1987, 44:36-44.
41. Gillin J.C., Buchsbaum M.S., Jacobs L.S., Fram D.H., Williams R.B., Vaughan T.B., et al. Partial REM sleep deprivation, schizophrenia and field articulation. Arch Gen Psychiatry 1974, 30:653-662.
42. 2 receptors for antipsychotic activity. Current antipsychotics: handbook of experimental pharmacology 2012, 212:27-52. Springer-Verlag, Heidelberg. G. Gross, M.A. Geyer (Eds.).
43. Hajak G., Rodenbeck A., Bandelow B., Friedrichs S., Huether G., Rüther E. Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects. Eur Neuropsychopharmacol 1996, 6:149-153.
44. Hamdi A. Melatonin administration increases the affinity of D2 dopamine receptors in the rat striatum. Life Sci 1998, 63:2115-2120.
45. Hardeland R. Investigational melatonin receptor agonists. Expert Opin Investig Drugs 2010, 19:747-764.
46. Hardeland R., Cardinali D.P., Srinivasan V., Spence D.W., Brown G.M., Pandi-Perumal S.R. Melatonin - a pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2011, 93:350-384.
47. Hashimoto K., Ueda S., Ehara A., Sakakibara S., Yoshimoto K., Hirata K. Neuroprotective effects of melatonin on the nigrostriatal dopamine system in the zitter rat. Neurosci Lett 2012, 506:79-83.
48. Hobson J.A., Stickgold R., Pace-Schott E.F. The neuropsychology of REM sleep dreaming. Neuroreport 1998, 9:R1-R14.
49. Imbesi M., Arslan A.D., Yildiz S., Sharma R., Gavin D., Tun N., et al. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal 'clock' gene expression in striatal neurons in vitro. J Pineal Res 2009, 46:87-94.
50. Iuvone P.M., Gan J. Functional interaction of melatonin receptors and D1 dopamine receptors in cultured chick retinal neurons. J Neurosci 1995, 15:2179-2185.
51. Jaliffa C.O., Lacoste F.F., Llomovatte D.W., Sarmiento M.I., Rosenstein R.E. Dopamine decreases melatonin content in golden hamster retina. J Pharmacol Exp Ther 2000, 293:91-95.
52. Janowsky D.S., Davis J.M., El-Yousef M.K., Sekerhe H.J. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972, 2:632-635.
53. Jus K., Bouchard M., Jus A.K., Villeneuve A., Lachance R. Sleep EEG studies in untreated, long-term schizophrenic patients. Arch Gen Psychiatry 1973, 29:386-390.
54. Kaasinen V., Jokinen P., Joutsa J., Eskola O., Rinne J.O. Seasonality of striatal dopamine synthesis capacity in Parkinson's disease. Neurosci Lett 2012, 530:80-84.
55. Kabuto M., Namura I., Saitoh Y. Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans. Endocrinol Jpn 1986, 33:405-414.
56. Kempenaers C., Kerkhofs M., Linkowski P., Mendlewicz J. Sleep EEG variables in young schizophrenic and depressive patients. Biol Psychiatry 1988, 24:833-838.
57. Keshavan M.S., Reynolds C.F., Kupfer D.J. Electroencephalographic sleep in schizophrenia: a critical review. Comp Psychiatry 1990, 31:34-47.
58. Khaldy H., Leon J., Escames G., Bikjdaouene L., Garcia J., Acuna-Castroviejo D. Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment. Neuroendocrinology 2002, 75:201-208.
59. Kishi T., Kitajima T., Ikeda M., Yamanouchi Y., Kinoshita Y., Kawashima K., et al. Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur Arch Psychiatry Clin Neurosci 2009, 259:293-297.
60. Kluge M., Himmerich H., Wehmeier P.M., Rummel-Kluge C., Dalal M., Hinze-Selch D., et al. Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine. Schizophr Res 2012, 135:123-127.
61. Ko C.H., Takahashi J.S. Molecular components of the mammalian circadian clock. Hum Mol Genet 2006, 15:R271-R277. [Spec. No. 2].
62. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996, 93:9235-9240.
63. Lauer C.J., Krieg J.C. Slow-wave sleep and ventricular size: a comparative study in schizophrenia and major depression. Biol Psychiatry 1998, 44:121-128.
64. Lauer C.J., Schreiber W., Pollmächer T., Holsboer F., Krieg J.C. Sleep in schizophrenia: a polysomnographic study of drug-naive patients. Neuropsychopharmacology 1997, 16:51-60.
65. Leger D., Laudon M., Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004, 116:91-95.
66. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 2003, 73:34-48.
67. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008, 31:234-242.
68. Lowenstein P.R., Rosenstein R., Caputti E., Cardinali D.P. Benzodiazepine binding sites in human pineal gland. Eur J Pharmacol 1984, 106:399-403.
69. Mann K., Rossbach W., Müller M.J., Müller-Siecheneder F., Pott T., Linde I., et al. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 2006, 31:256-264.
70. Mansour H.A., Wood J., Logue T., Chowdari K.V., Dayal M., Kupfer D.J., et al. Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav 2006, 5:150-157.
71. Mazzoccoli G., Pazienza V., Vinciguerra M. Clock genes and clock-controlled genes in the regulation of metabolic rhythms. Chronobiol Int 2012, 29:227-251.
72. McCrae C.S., Lichstein K.L. Secondary insomnia: diagnostic challenges and intervention opportunities. Sleep Med Rev 2001, 5:47-61.
73. Meyer-Lindenberg A. Neuroimaging and the question of neurodegeneration in schizophrenia. Prog Neurobiol 2011, 95:514-516.
74. Mills J.N., Morgan R., Minors D.S., Waterhouse J.M. The free-running circadian rhythms of two schizophrenics. Chronobiologia 1977, 4:353-360.
75. Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther 2009, 15:32-51.
76. Monteleone P., Maj M., Fusco M., Kemali D., Reiter R.J. Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophr Res 1992, 7:77-84.
77. Monti J.M. Primary and secondary insomnia: prevalence, causes and current therapeutics. Curr Med Chem - CNS Agents 2004, 4:119-137.
78. Monti J.M., Monti D. Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 2004, 4:263-276.
79. Monti J.M., Hawkins M., Jantos H., D'Angelo L., Fernandez R. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology (Berl) 1988, 95:395-400.
80. Monti J.M., Jantos H., Fernandez M. Effects of the dopamine D-2 receptor agonist, quinpirole on sleep and wakefulness in the rat. Eur J Pharmacol 1989, 169:61-66.
81. Morera-Fumero A.L., Abreu-Gonzalez P. Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression. J Clin Psychopharmacol 2010, 30:739-741.
82. Morgenthaler T.I., Lee-Chiong T., Alessi C., Friedman L., Aurora R.N., Boehlecke B., et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep 2007, 30:1445-1459.
83. Nofzinger F.A., Van Kammen D.P., Gilbertson M.W., Gurklis J.A., Peters J.L. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free. Biol Psychiatry 1993, 33:829-835.
84. Oliver P.L., Sobczyk M.V., Maywood E.S., Edwards B., Lee S., Livieratos A., et al. Disrupted circadian rhythms in a mouse model of schizophrenia. Curr Biol 2012, 22:314-319.
85. Owen F., Ferrier I.N., Poulter M., Crow T.J. Hydroxy-indole-o-methyltransferase activity in human pineals: a comparison of controls and schizophrenics. Clin Endocrinol (Oxf) 1983, 19:313-317.
86. Panda S., Sato T.K., Castrucci A.M., Rollag M.D., DeGrip W.J., Hogenesch J.B., et al. Melanopsin (Opn4) requirement for normal light-induced circadian phase shifting. Science 2002, 298:2213-2216.
87. Park H.J., Park J.K., Kim S.K., Cho A.R., Kim J.W., Yim S.V., et al. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci 2011, 45:304-308.
88. Peng Z.W., Chen X.G., Wei Z. Cryptochrome1 may be a candidate gene of schizophrenia. Med Hypotheses 2007, 69:849-851.
89. Poulin J., Daoust A.M., Forest G., Stip I., Godbout R. Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia. Schizophr Res 2003, 62:147-153.
90. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., et al. International Schizophrenia Consortium: common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
91. Rao M.L., Gross G., Strebel B., Halaris A., Huber G., Bräunig P., et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 1994, 35:151-163.
92. Ritsner M., Kurs R., Ponizovsky A., Hadjez J. Perceived quality of life in schizophrenia: relationship to sleep quality. Qual Life Res 2004, 13:783-791.
93. Robinson S., Rosca P., Durst R., Shai U., Ghinea C., Schmidt U., et al. Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients. Acta Psychiatr Scand 1991, 84:221-224.
94. Ross N.L., Mavrogiannis L.A., Sargent C.A., Knight S.J., Wadekar R., DeLisi L.E., et al. Quantitation of X-Y homologous genes in patients with schizophrenia by multiplex polymerase chain reaction. Psychiatr Genet 2003, 13:115-119.
95. Savaskan E., Olivieri G., Meier F., Brydon L., Jockers R., Ravid R., et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 2002, 32:59-62.
96. Savaskan E., Ayoub M.A., Ravid R., Angeloni D., Fraschini F., Meier F., et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005, 38:10-16.
97. Savaskan E., Jockers R., Ayoub M., Angeloni D., Fraschini F., Flammer J., et al. The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease. Curr Alzheimer Res 2007, 4:47-51.
98. Scher J., Wankiewicz E., Brown G.M., Fujieda H. MT(1) melatonin receptor in the human retina: expression and localization. Invest Ophthalmol Vis Sci 2002, 43:889-897.
99. Shamir E., Laudon M., Barak Y., Anis Y., Rotenberg V., Elizur A., et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry 2000, 61:373-377.
100. Shamir E., Rotenberg V.S., Laudon M., Zisapel N., Elizur A. First-night effect of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol 2000, 20:691-694.
101. Singhal N.K., Srivastava G., Agrawal S., Jain S.K., Singh M.P. Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?. Mol Neurobiol 2012, 45:186-199.
102. Song Y., Chan C.W., Brown G.M., Pang S.F., Silverman M. Studies of the renal action of melatonin: Evidence that the effects are mediated by 37kDa receptors of the Mel1a subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J 1997, 11:93-100.
103. Spadoni G., Bedini A., Rivara S., Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther 2011, 17:733-741.
104. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
105. Stern M., Fram D.H., Wyatt R., Grinspoon L., Tursky B. All-night sleep studies of acute schizophrenics. Arch Gen Psychiatry 1969, 20:470-477.
106. Strecker G.J., Park W.K., Dudek F.E. Zinc and flunitrazepam modulation of GABA-mediated currents in rat suprachiasmatic neurons. J Neurophysiol 1999, 81:184-191.
107. Suresh Kumar P.N., Andrade C., Bhakta S.G., Singh N.M. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry 2007, 68:237-241.
108. Taheri S., Zeitzer J.M., Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Ann Rev Neurosci 2002, 25:283-313.
109. Takao T., Tachikawa H., Kawanishi Y., Mizukami K., Asada T. CLOCK gene T3111C polymorphism is associated with Japanese schizophrenics: a preliminary study. Eur Neuropsychopharmacol 2007, 17:273-276.
110. Tandon R., Shipley J.E., Taylor S., Greden J.F., Eise A., DeQuardo J., et al. Electroencephalographic sleep abnormalities in schizophrenia. Relationship to positive/negative symptoms and prior neuroleptic treatment. Arch Gen Psychiatry 1992, 49:185-194.
111. Thaker G.K., Wagman A.M.I., Tamminga C.A. Sleep polygraphy in schizophrenia: methodological issues. Biol Psychiatry 1990, 28:240-246.
112. Thompson P.M., Rosenberger C., Qualls C. CSF SNAP-25 in schizophrenia and bipolar illness. A pilot study. Neuropsychopharmacology 1999, 21:717-722.
113. Thompson P.M., Egbufoama S., Vawter M.P. SNAP-25 reduction in the hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:411-417.
114. Thompson P.M., Kelley M., Yao J., Tsai G., van Kammen D.P. Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Biol Psychiatry 2003, 53:1132-1137.
115. Turek F.W., Gillette M.U. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004, 5:523-532.
116. Uz T., Arslan A.D., Kurtuncu M., Imbesi M., Akhisaroglu M., Dwivedi Y., et al. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res 2005, 136:45-53.
117. Van Kammen D.P., Van Kammen W.B., Peters J.L., Rosen J., Slawsky R.C., Neylan T. CSF MHPG, sleep and psychosis in schizophrenia. Clin Neuropharmacol 1986, 9(Suppl. 4):575-577.
118. Wan Q., Man H.Y., Liu F., Braunton J., Niznik H.B., Pang S.F., et al. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci 1999, 2:401-403.
119. Wassef A.A., Dott S.G., Harris A., Brown A., O'Boyle M., Meyer W.J., et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999, 19:222-232.
120. Wassef A., Baker J., Kochan L.D. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 2003, 23:601-640.
121. Wilson S.J., Nutt D.J., Alford C., Argyropoulos S.V., Baldwin D.S., Bateson A.N., et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010, 24:1577-1601.
122. Wirz-Justice A., Cajochen C., Nussbaum P. A schizophrenic patient with an arrhythmic circadian rest-activity cycle. Psychiatry Res 1997, 73:83-90.
123. Wirz-Justice A., Haug H.J., Cajochen C. Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs?. Schizophr Bull 2001, 27:497-502.
124. Wirz-Justice A., Bromundt V., Cajochen C. Circadian disruption and psychiatric disorders: the importance of entrainment. Sleep Med Clin 2009, 4:273-284.
125. Wulff K., Joyce E., Middleton B., Dijk D.J., Foster R.G. The suitability of actigraphy, diary data, and urinary melatonin profiles for quantitative assessment of sleep disturbances in schizophrenia: a case report. Chronobiol Int 2006, 23:485-495.
126. Wulff K., Gatti S., Wettstein J.G., Foster R.G. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat Rev Neurosci 2010, 11:589-599.
127. Wulff K., Dijk D.J., Middleton B., Foster R.G., Joyce E.M. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry 2012, 200:308-316.
128. Young C.E., Arima K., Xie J., Hu L., Beach T.G., Falkai P., et al. SNAP-25 deficit and hippocampal connectivity in schizophrenia. Cereb Cortex 1998, 8:261-268.
129. Yujnovsky I., Hirayama J., Doi M., Borrelli E., Sassone-Corsi P. Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proc Natl Acad Sci U S A 2006, 103:6386-6389.
130. Zhang J., Liao G., Liu C., Sun L., Liu Y., Wang Y., et al. The association of CLOCK gene T3111C polymorphism and hPER3 gene 54-nucleotide repeat polymorphism with Chinese Han people schizophrenics. Mol Biol Rep 2011, 38:349-354.
131. Zhdanova I.V., Wurtman R.J., Regan M.M., Taylor J.A., Shi J.P., Leclair O.U. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001, 86:4727-4730.
132. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol 2001, 21:605-616.
133. Zisapel N., Laudon M. Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro: inhibition by melatonin. Biochem Biophys Res Commun 1982, 104:1610-1616.
134. Zisapel N., Egozi Y., Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res 1982, 246:161-163.